Archives of Dermatological Research

, Volume 310, Issue 10, pp 785–793 | Cite as

Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case–control study

  • Neslihan AkdoganEmail author
  • Nuran Alli
  • Pinar Incel Uysal
  • Canan Topcuoglu
  • Tuba Candar
  • Turan Turhan
Original Paper


Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. HS has been associated with obesity, adipokine imbalance, dyslipidemia, pro-inflammation, and metabolic syndrome (MS). The aim of this study was to determine the association between HS, and serum visfatin levels (SVLs), small-dense low-density lipoprotein cholesterol (sdLDL-C), and ischemia-modified albumin (IMA), as well as the association between HS, and smoking, alcohol consumption, anthropometric measurements, blood pressures (BPs), fasting blood glucose (FBG) and lipids, inflammatory markers, homocysteine, uric acid (UA), serum insulin levels (SILs), insulin resistance (IR) and MS, so as to identify relevant risk factors for HS. This case–control study included 40 patients (M/F: 23/17) and 40 age- and gender-matched controls (M/F: 23/17). Demographic data, smoking status and alcohol consumption, personal and family medical history, previous and current treatments were noted. Anthropometric data, BPs, FBG and lipids, homocysteine, UA, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP), hemoglobin A1c (HbA1c), SILs, SVLs, IMA and sdLDL-C were measured. Homeostasis model assessment for IR (HOMA-IR) was calculated. The associations were made by univariate and multivariate analyses. Univariate analysis showed that there was a significant association between HS and smoking, pack-years of smoking, weight, body mass index (BMI), waist circumference (WC), triglycerides (TGs), high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, SILs, CRP, hs-CRP, homocysteine, UA, ESR, HOMA-IR, SVLs, and MS. After adjusting for BMI and smoking status, the SVLs, SILs, and hs-CRP levels remained higher in the patients than in the controls (P = 0.02, P = 0.01, and P = 0.02, respectively). Multivariate analysis showed that there was a significant association between HS, and the SVLs and SILs, and smoking. Each unit increase in the SVL (P = 0.003, 95% CI 1.16–2.11) and SIL (P = 0.03, 95% CI 1.01–1.17) increased the risk of HS 1.56- and 1.09-fold, respectively. Furthermore, smoking was associated with a 14.87-fold increase in the risk of HS (P = 0.001, 95% CI 2.82–78.56). This study indicates that HS patients have higher SVLs, SILs, and hs-CRP levels than healthy controls—independent of BMI and smoking status. The SVL and SILs and smoking were independent risk factors for HS.


Hidradenitis suppurativa Visfatin Insulin Smoking 



This study was supported by Scientific Research Support Fund of Ankara Numune Training and Research Hospital on December 14, 2016 (Grant number: 2016/1089).

Compliance with ethical standards

Conflict of interest

Author Neslihan Akdogan, Nuran Alli, Pinar Incel Uysal, Canan Topcuoglu, Tuba Candar and Turan Turhan declare that they have no conflict of interest.

Ethical approval

The study protocol was approved by the Ankara Numune Training and Research Hospital Ethics Committee (code E-16-1089, 14 December 2016). All study procedures were performed in accordance with the ethical principles of the 1964 Declaration of Helsinki, and all the participants provided written informed consent.


  1. 1.
    Campanati A, Ganzetti G, Giuliodori K, Marra M, Bonfigli A, Testa R, Offidani A (2015) Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-alpha inhibitors: results of a retrospective analysis. Int J Dermatol 54(7):839–845CrossRefGoogle Scholar
  2. 2.
    Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115(8):972–980CrossRefGoogle Scholar
  3. 3.
    Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434CrossRefGoogle Scholar
  4. 4.
    Eknoyan G (2008) Adolphe Quetelet (1796–1874)—the average man and indices of obesity. Nephrol Dial Transplant 23(1):47–51CrossRefGoogle Scholar
  5. 5.
    Esteghamati A, Morteza A, Zandieh A, Jafari S, Rezaee M, Nakhjavani M, Jamali A, Esteghamati AR, Khalilzadeh O (2012) The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis. J Cardiovasc Transl Res 5(4):541–546CrossRefGoogle Scholar
  6. 6.
    Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Kiess W, Körner A (2011) Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 54(5):1200–1211CrossRefGoogle Scholar
  7. 7.
    Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430CrossRefGoogle Scholar
  8. 8.
    Garg A, Papagermanos V, Midura M, Strunk A (2018) Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the USA. Br J Dermatol 178(3):709–714CrossRefGoogle Scholar
  9. 9.
    Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U (2012) Leptin, adiponectin, visfatin and retinol-binding protein-4— mediators of comorbidities in patients with psoriasis? Exp Dermatol 21(1):43–47CrossRefGoogle Scholar
  10. 10.
    Gold DA, Reeder VJ, Mahan MG, Hamzavi IH (2014) The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 70(4):699–703CrossRefGoogle Scholar
  11. 11.
    Grolla AA, Travelli C, Genazzani AA, Sethi JK (2016) Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine. Br J Pharmacol 173(14):2182–2194CrossRefGoogle Scholar
  12. 12.
    Grzywocz P, Mizia-Stec K, Wybraniec M, Chudek J (2015) Adipokines and endothelial dysfunction in acute myocardial infarction and the risk of recurrent cardiovascular events. J Cardiovasc Med (Hagerstown) 16(1):37–44Google Scholar
  13. 13.
    International Diabetes Federation (2006) The IDF consensus worldwide definition of the metabolic syndrome. Brussels, Belgium: International Diabetes Federation. 2006.
  14. 14.
    Kucuk A, Uslu AU, Arslan S, Balta S, Ozturk C, Uysal S, Yılmaz R, Sakız D, Kayrak M (2016) Ischemia-modified albumin and atherosclerosis in patients with familial Mediterranean fever. Angiology 67(5):456–460CrossRefGoogle Scholar
  15. 15.
    Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis E, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J, Zouboulis CC (2008) What causes hidradenitis suppurativa? Exp Dermatol 17(5):455–456CrossRefGoogle Scholar
  16. 16.
    Lee YH, Bae SC (2018) Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Int J Rheum Dis 21(3):664–672CrossRefGoogle Scholar
  17. 17.
    Malara A, Hughes R, Jennings L, Sweeney CM, Lynch M, Awdeh F, Timoney I, Tobin AM, Lynam-Loane K, Tobin L, Hogan A, O’Shea D, Kirby B (2018) Adipokines are dysregulated in patients with hidradenitis suppurativa. Br J Dermatol 178(3):792–793CrossRefGoogle Scholar
  18. 18.
    Maron BA, Loscalzo J (2009) The treatment of hyperhomocysteinemia. Ann Rev Med 60:39–54CrossRefGoogle Scholar
  19. 19.
    Mattu HS, Randeva HS (2013) Role of adipokines in cardiovascular disease. J Endocrinol 216(1):T17–T36CrossRefGoogle Scholar
  20. 20.
    Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, Jemec GB (2014) Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 150(12):1273–1280CrossRefGoogle Scholar
  21. 21.
    Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178(3):1748–1758CrossRefGoogle Scholar
  22. 22.
    Prens E, Deckers I (2015) Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol 73(5 Suppl 1):S8–S11CrossRefGoogle Scholar
  23. 23.
    Seshadri Reddy V, Bukke S, Munikumar M (2018) Elevated levels of the circulatory ischemia-modified albumin in patients with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol 14:1–7Google Scholar
  24. 24.
    Shaker O, El-Shehaby A, Zakaria A, Mostafa N, Talaat S, Katsiki N, Mikhailidis DP (2011) Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. Clin Biochem 44(17–18):1457–1463CrossRefGoogle Scholar
  25. 25.
    Shalom G, Freud T, Harman-Boehm I, Polishchuk I, Cohen AD (2015) Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol 173(2):464–470CrossRefGoogle Scholar
  26. 26.
    Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH (2017) Hidradenitis suppurativa: an update on connecting the tracts. F1000Res 6:1272CrossRefGoogle Scholar
  27. 27.
    Soltani Z, Rasheed K, Kapusta DR, Reisin E (2013) Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep 15(3):175–181CrossRefGoogle Scholar
  28. 28.
    Sun K, Song J, Liu K, Fang K, Wang L, Wang X, Li J, Tang X, Wu Y, Qin X, Wu T, Gao P, Chen D, Hu Y (2017) Associations between homocysteine metabolism related SNPs and carotid intima-media thickness: a Chinese sib pair study. J Thromb Thrombolysis 43(3):401–410CrossRefGoogle Scholar
  29. 29.
    Sun Y, Wu Z, Wei L, Liu C, Zhu S, Tang S (2015) High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis. Gynecol Endocrinol 31(10):808–814CrossRefGoogle Scholar
  30. 30.
    Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GB (2015) Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 173(5):1142–1155CrossRefGoogle Scholar
  31. 31.
    Vilanova I, Hernandez JL, Mata C, Duran C, Garcia-Unzueta MT, Portilla V, Fuentevilla P, Corrales A, González-Vela MC, González-Gay MA, Blanco R, González-López MA (2018) Insulin resistance in hidradenitis suppurativa: a case–control study. J Eur Acad Dermatol Venereol 32(5):820–824CrossRefGoogle Scholar
  32. 32.
    World Health Organization (2008) Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008. World Health Organization, Geneva.
  33. 33.
    Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB (2015) Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231(2):184–190CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Dermatology and VenereologyAnkara Numune Education and Research HospitalAnkaraTurkey
  2. 2.Department of Medical BiochemistryAnkara Numune Training and Research HospitalAnkaraTurkey
  3. 3.Department of Medical Biochemistry, Faculty of MedicineUfuk UniversityAnkaraTurkey

Personalised recommendations